Lactiplantibacillus plantarum as a multifunctional probiotic for inflammatory bowel disease: Mechanisms, synbiotic strategies, and delivery systems.
Lactiplantibacillus plantarum shows promise as a probiotic for IBD, but further research is needed to translate these findings into clinical practice.
Where it sits
this study against the rest of the survodutide (bi 456906) corpusSummary and findings
The review discusses the role of Lactiplantibacillus plantarum in managing inflammatory bowel disease (IBD) through modulation of the intestinal microenvironment. It explores the probiotic's mechanisms, synbiotic strategies, and delivery systems. The paper emphasizes the need for integrating basic research with clinical applications.
Abstract
Inflammatory bowel disease (IBD) encompasses a group of chronic inflammatory disorders of the bowel, characterized by complex etiologies that are closely associated with an imbalance in intestinal microbiota, abnormal immune activation, and compromised intestinal mucosal barrier function. Current therapeutic options are limited by low response rates and metabolic disorders, underscoring the urgent need for innovative clinical treatments. Lactiplantibacillus plantarum (formerly Lactobacillus plantarum, hereafter referred to as L. plantarum) has emerged as a focal point in IBD research due to its capacity to modulate the intestinal microenvironment and its robust probiotic properties. This review elucidates the multifaceted regulatory mechanisms of L. plantarum in IBD, including its role in modulating host immune responses, mitigating oxidative damage, restoring intestinal mucosal barrier integrity, and reestablishing microbiota balance. Additionally, it highlights advancements in L. plantarum synbiotic research and underscores the necessity for a "basic research-technology translation-clinical application" framework in future investigations, while also exploring the potential of novel targeted delivery technologies. Evidence indicates that L. plantarum enhances intestinal health through multi-target synergy, with its probiotic effects and innovative delivery systems presenting significant application potential. This review offers insights into the mechanisms underlying the action of L. plantarum, establishing a theoretical foundation for the development of novel food therapies aimed at treating IBD. It further contributes to the integration of such therapies within precision medicine approaches for IBD.
Background
Inflammatory bowel disease (IBD) is a chronic condition characterized by inflammation of the bowel, often linked to microbiota imbalance and immune dysfunction. Current treatments have limited efficacy and can cause metabolic issues. This review focuses on Lactiplantibacillus plantarum, a probiotic with potential to improve IBD outcomes by modulating the intestinal environment.
Methods
This is a review article that synthesizes existing literature on Lactiplantibacillus plantarum's role in IBD. It discusses mechanisms of action, synbiotic strategies, and delivery systems without presenting new experimental data.
Results
Not reported in abstract.
Interpretation
The review suggests that Lactiplantibacillus plantarum has multifaceted benefits for IBD management, potentially enhancing intestinal health through immune modulation and microbiota balance. However, the lack of new data and reliance on existing studies limit the ability to draw definitive conclusions about clinical efficacy.
Key findings
- Lactiplantibacillus plantarum modulates host immune responses.
- Lactiplantibacillus plantarum mitigates oxidative damage.
- Lactiplantibacillus plantarum restores intestinal mucosal barrier integrity.
- Lactiplantibacillus plantarum reestablishes microbiota balance.
Limitations
- No new experimental data presented.
- Relies on existing literature.
- Lacks quantitative findings.
- Focuses on theoretical mechanisms.